A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07200479 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory B-Cell Neoplasms

Interventions

DRUG: CAR T cells chimeric antigen receptor cells

Sponsor

Institute of Hematology & Blood Diseases Hospital, China